Category Archives: R&D

Medical Marijuana Trials: Pre-empted by Politics

There has been a lot of debate on the therapeutic use of marijuana. There are currently 24 states that have legalized marijuana for medical use. Most recently, two states, Washington and Colorado, have legalised the drug for recreational use. While there is literature that suggests benefits of marijuana for medicinal use, particularly in animal models, […]
Also posted in Guest Blog, healthcare, People | Tagged , , , , | Leave a comment

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Also posted in Deals, Emerging Markets, Europe, Global, Guest Blog, Strategy | Tagged , , | Leave a comment

More Than Half of US Approved Drugs Developed by Collaborating Companies

According to the Tufts Center for the Study of Drug Development R&D Management Report, more than half of all new drugs approved in the US between 2000 and 2011 were developed by companies that collaborated in one form or another with other entities. The report is based on insights gathered at an executive roundtable of […]
Posted in R&D | Tagged | Leave a comment

BMS to Push Innovation in US Universities

Bristol-Myers Squibb (BMS) andĀ Allied Minds haveĀ formed Allied-Bristol Life Sciences LLC, a new enterprise to identify and foster research and preclinical development of biopharmaceutical innovations from leading university research institutions across the US. Allied-Bristol Life Sciences will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development and, ultimately, […]
Posted in R&D | Tagged , , | Leave a comment

Risk and Innovation in Biopharma: A CEO’s Perspective

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data. Click here for the article.
Also posted in Biotech, Guest Blog, leadership, Strategy | Tagged , | Leave a comment
  • Categories

  • Meta